Arcus Biosciences (NYSE:RCUS - Get Free Report) released its earnings results on Wednesday. The company reported ($1.00) EPS for the quarter, topping analysts' consensus estimates of ($1.06) by $0.06, Briefing.com reports. The company had revenue of $48.00 million for the quarter, compared to analysts' expectations of $38.95 million. Arcus Biosciences had a negative return on equity of 42.86% and a negative net margin of 100.81%. The business's revenue for the quarter was up 50.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.94) EPS.
Arcus Biosciences Stock Up 4.7 %
NYSE:RCUS traded up $0.74 on Thursday, hitting $16.47. The stock had a trading volume of 2,495,273 shares, compared to its average volume of 734,657. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -5.09 and a beta of 0.89. The business's 50-day simple moving average is $16.61 and its two-hundred day simple moving average is $16.03. Arcus Biosciences has a 52-week low of $12.95 and a 52-week high of $20.31.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on RCUS shares. Barclays lifted their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Friday, October 25th. Wedbush reissued an "outperform" rating and issued a $30.00 price objective on shares of Arcus Biosciences in a report on Thursday, October 3rd. Evercore ISI raised Arcus Biosciences to a "strong-buy" rating in a report on Friday, August 9th. Wells Fargo & Company assumed coverage on Arcus Biosciences in a report on Tuesday, October 8th. They issued an "overweight" rating and a $29.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcus Biosciences in a report on Thursday, October 3rd. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $33.67.
View Our Latest Analysis on Arcus Biosciences
Arcus Biosciences Company Profile
(
Get Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Featured Stories
Before you consider Arcus Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.
While Arcus Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.